Nephrolog/Vanderbilt
Nephrology
Dr. Thomas A. Golper, MD
|
|
Give Review
Thomas Golper works in the field of Nephrology. He went to Indiana University School of Medicine. Indiana University School of Medicine has a rank of 45 in research and a 47 in primary care He over the years received 2 awards: "Fellow" and "Fellow (ASNF)". Thomas Golper is also published. He has 100 publications published. The lastest publication: "Implementation of the Peritoneal Dialysis Adequacy Guidelines: a personal perspective.' Dr. Thomas A. Golper accepts all Medicare patients.
Publications
- Is hemodiafiltration ready for broader use?
- Twice-Weekly and Incremental Hemodialysis Treatment for Initiation of Kidney Replacement Therapy.
- Does Hemodialyzer Reuse Have a Place in Current ESRD Care: "To Be or Not To Be?"
- Comparative Outcomes Between Continuous Ambulatory and Automated Peritoneal Dialysis: A Narrative Review.
- The Possible Impact of the US Prospective Payment System ("Bundle") on the Growth of Peritoneal Dialysis.
- Dancing around Elephants.
- Is dorothy correct? The role of patient education in promoting home dialysis.
- How to overcome barriers and establish a successful home HD program.
- In reply to 'a large dialysis provider committed to home modalities'.
- Systematic Barriers to the Effective Delivery of Home Dialysis in the United States: A Report From the Public Policy/Advocacy Committee of the North American Chapter o...
- Dialysate Flow Rate and Delivered Kt/Vurea for Dialyzers With Enhanced Dialysate Flow Distribution.
- C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic Kidney disease not on dialysis.
- Low-efficiency Acute renal replacement therapy: role in Acute kidney injury.
- The patient-centered medical home: managed care repackaged or something better?
- Technical breakthroughs in the wearable artificial Kidney (WAK).
- Dialysate ... Ho-hum!
- Learning about the practice of peritoneal dialysis.
- New challenges and paradigms for mid-career faculty in academic medical centers: key strategies for success for mid-career medical school faculty.
- Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialysis.
- Predialysis nephrology care improves dialysis outcomes: now what? Or chapter two.
- Frequency of physician visits to patients on in-center maintenance hemodialysis: does one strategy fit all?
- L-carnitine treatment of anemia.
- Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring Renal replacement therapy.
- Drug dosing consideration in patients with Acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).
- Home dialysis in the new USA bundled payment plan: implications and impact.
- The financial implications for Medicare of greater use of peritoneal dialysis.
- Hybrid Renal replacement therapies for critically ill patients.
- The importance of residual Renal function for patients on dialysis.
- Drug-induced Acute kidney injury.
- Downloadable computer models for maintenance but not Acute renal replacement therapy.
- Blood pressure targets in hemodialysis patients.
- Glucagonoma syndrome in a 19-year-old woman.
- Adrenocorticotropin-cortisol axis abnormalities in hemodialysis patients.
- Primary cadaver Kidney transplantation in older patients: survival equal to dialysis.
- Intestinal bypass and urine oxalate.
- Hybrid Renal replacement modalities for the critically ill.
- Update on drug sieving coefficients and dosing adjustments during continuous Renal replacement therapies.
- Incremental dialysis.
- Sustained low-efficiency dialysis for critically ill patients requiring Renal replacement therapy.
- Vancomycin revisited.
- The Peritoneal Dialysis Multicenter Infection Study Project (MISP) under the auspices of the International Studies Committee of the International Society for Peritonea...
- Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study.
- Dose and adequacy.
- The rationale for improving outcomes on dialysis by actions prior to and at initiation.
- Drug dosing adjustments during continuous Renal replacement therapies.
- Noncompliance in hemodialysis: predictors and survival analysis.
- Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation.
- Cefazolin as empiric therapy in hemodialysis-related Infections: efficacy and blood concentrations.
- Plasma iohexol clearance in automated peritoneal dialysis--its role in adequacy determination.
- Implementation of the Peritoneal Dialysis Adequacy Guidelines: a personal perspective.
- Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients.
- Indications, technical considerations, and strategies for Renal replacement therapy in the intensive care unit.
- Morbidity and mortality in redefining adequacy of peritoneal dialysis: a step beyond the National Kidney Foundation Dialysis Outcomes Quality Initiative.
- The rationale for Healthy Start dialysis.
- Tumour lysis syndrome complicating high-dose treatment in patients With multiple myeloma.
- Impaired biological activity of erythropoietin by cyanate carbamylation.
- Methods used to evaluate the quality of evidence underlying the National Kidney Foundation-Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: descripti...
- Should we treat patients With incremental dialysis prescriptions?
- Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update.
- Are both creatinine and urea clearances necessary as indices of small solute clearance adequacy in peritoneal dialysis?
- Indications for vancomycin in dialysis patients.
- Continuous quality improvement: DOQI becomes K/DOQI and is updated. National Kidney Foundation''s Dialysis Outcomes Quality Initiative.
- The effect of recombinant erythropoietin on the early hematocrit rise after CAPD initiation.
- Ciprofloxacin and plasmids in staphylococci.
- Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients.
- Drug removal during continuous hemofiltration or hemodialysis.
- Tobramycin clearance during simulated continuous arteriovenous hemodialysis.
- The role of convection during simulated continuous arteriovenous hemodialysis.
- The effect of tobramycin on the Renal handling of vancomycin.
- Continuous arteriovenous hemofiltration in the critically ill patient.
- Low-dose recombinant human erythropoietin therapy in Chronic hemodialysis patients.
- Comparison of large volume culture to other methods for isolation of microorganisms from dialysate.
- The treatment of anemia With low-dose recombinant human erythropoietin.
- Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects.
- Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects.
- Reduction of cyst volume for symptomatic management of autosomal dominant polycystic Kidney disease.
- Comparison of two commercial broth-culture systems for microbial detection in dialysates of patients on continuous ambulatory peritoneal dialysis.
- Lovastatin in the treatment of multifactorial hyperlipidemia associated With proteinuria.
- Backtransport of dialysate solutes during in vitro continuous arteriovenous hemodialysis.
- Drug removal by continuous arteriovenous haemofiltration. A review of the evidence in poisoned patients.
- Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic Kidneys.
- Vancomycin pharmacokinetics, Renal handling, and nonRenal clearances in normal human subjects.
- Ciprofloxacin activity in cyst fluid from polycystic Kidneys.
- Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis.
- Sieving characteristics of a new polysulfone hemofilter for use With continuous arterio-venous hemofiltration.
- Analysis of the causative pathogens in uncomplicated CAPD-associated peritonitis: duration of therapy, relapses, and prognosis.
- Clinical characteristics and diagnostic considerations in acquired renal Cystic disease.
- Transmembrane pressures generated by filtrate line suction maneuvers and predilution fluid replacement during in vitro continuous arteriovenous hemofiltration.
- A multicenter trial to evaluate the use of the CAPD "O" set.
- Early experience With continuous arteriovenous hemofiltration in critically ill pediatric patients.
- The role of circulating mevalonate in nephrotic hypercholesterolemia in the rat.
- Gentamicin and phenytoin sieving through hollow-fiber polysulfone hemofilters.
- Continuous arteriovenous hemofiltration in Acute renal failure.
- Diagnostic value of creatine kinase and creatine kinase MB isoenzyme in Chronic hemodialysis patients: a longitudinal study.
- Removal of therapeutic drugs by continuous arteriovenous hemofiltration.
- Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations.
- Efficacy of minoxidil in the treatment of severe hypertension in systemic Disorders.
- Drug prescribing in renal Failure: dosing guidelines for adults.
- Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin.
Schools
Indiana University School Of Medicine
Oreg Hosps Clins
Oreg Health Science Center
Procedures Preformed
- End-Stage Renal Disease Related Services
- Hemodialysis
- Peritoneal Dialysis
Conditions Treated
- Acidosis
- Acute Glomerulonephritis
- Acute Kidney Failure
- Amyloidosis
- View All
Doctors Specialties
- Nephrology
Accepted Insurances
Awards
- Fellow
- Fellow (ASNF)
Education
-
Oregon Health & Science University -
Indiana University School of Medicine
Hospital
-
Vanderbilt Hospital and Clinics
Drug Facts
| NPI NUMBER | 1043229495 | |
| NPPES Provider LastName | GOLPER | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 372325100 | |
| NPPES Provider State | TN | |
| Specialty Description | Nephrology | |
| Total Claim Count | 1888.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 83.0 | |
| Percent Opioid Claims | 4.4 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1043229495 |
| Last Name Of The Provider | GOLPER |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
Dr. William H. Pettus, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. J H. Helderman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Salil Roy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Anthony Langone, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew Breyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alfred George, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James M. Luther, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arksarapuk Jittirat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leslie S. Gewin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harry R. Jacobson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine M. Oshel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Stone, MD |
|
|
Dr. Neil Sanghani, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kevin L. Cox, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Volker H. Haase, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Heidi Schaefer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chike M. Nzerve, MD |
|
|
Dr. Faris Ahmed, MD
This Doctor is OpenDoctor Recommended.
|